MA48971A - Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant - Google Patents

Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant

Info

Publication number
MA48971A
MA48971A MA048971A MA48971A MA48971A MA 48971 A MA48971 A MA 48971A MA 048971 A MA048971 A MA 048971A MA 48971 A MA48971 A MA 48971A MA 48971 A MA48971 A MA 48971A
Authority
MA
Morocco
Prior art keywords
tetrahydrate
ligand
pharmaceutical compositions
preparation process
compositions including
Prior art date
Application number
MA048971A
Other languages
English (en)
Other versions
MA48971B1 (fr
Inventor
Marc Capet
Jeanne-Marie Lecomte
Jean-Charles Schwartz
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of MA48971A publication Critical patent/MA48971A/fr
Publication of MA48971B1 publication Critical patent/MA48971B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne la forme tétrahydrate du composé : (3s)-4-{4-[3-(3-méthylpipéridin-1-yl)propoxy]phényl}pyridine 1-oxide, dichlorhydrate, son procédé de préparation et ses utilisations thérapeutiques.
MA48971A 2017-03-21 2018-03-20 Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant MA48971B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305310.9A EP3378858A1 (fr) 2017-03-21 2017-03-21 Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant
PCT/EP2018/056999 WO2018172344A1 (fr) 2017-03-21 2018-03-20 Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques les comprenant

Publications (2)

Publication Number Publication Date
MA48971A true MA48971A (fr) 2020-02-05
MA48971B1 MA48971B1 (fr) 2021-03-31

Family

ID=58488932

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48971A MA48971B1 (fr) 2017-03-21 2018-03-20 Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant

Country Status (23)

Country Link
US (1) US11078183B2 (fr)
EP (2) EP3378858A1 (fr)
JP (1) JP7235671B2 (fr)
KR (1) KR102608265B1 (fr)
CN (1) CN110891948B (fr)
AU (1) AU2018238260B2 (fr)
CA (1) CA3056490A1 (fr)
CY (1) CY1124114T1 (fr)
DK (1) DK3601252T3 (fr)
ES (1) ES2868024T3 (fr)
HR (1) HRP20210312T1 (fr)
HU (1) HUE053710T2 (fr)
IL (1) IL269360B2 (fr)
LT (1) LT3601252T (fr)
MA (1) MA48971B1 (fr)
MX (1) MX389167B (fr)
NZ (1) NZ757340A (fr)
PL (1) PL3601252T3 (fr)
PT (1) PT3601252T (fr)
RS (1) RS61511B1 (fr)
SM (1) SMT202100278T1 (fr)
WO (1) WO2018172344A1 (fr)
ZA (1) ZA201906202B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3378477A1 (fr) * 2017-03-21 2018-09-26 BIOPROJET Pharma Nouvelles utilisations thérapeutiques de ligands h3
PT3598975T (pt) 2018-07-27 2020-12-21 Bioprojet Soc Civ Novas combinações de um antagonista h3 e um inibidor da re-assimilação da noradrenalina, e suas utilizações terapêuticas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101060971B1 (ko) * 2002-05-14 2011-09-01 제노바 리미티드 안트라닐산 유도체 수화물의 제조 방법
WO2006059778A1 (fr) * 2004-12-01 2006-06-08 Banyu Pharmaceutical Co., Ltd. Dérivé substitué de pyridone
EP1717235A3 (fr) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines et leur utilisation comme ligands du récepteur histaminique H3
BR112014013461A2 (pt) * 2011-12-08 2017-06-13 Taisho Pharmaceutical Co Ltd derivado de fenilpirrol
WO2013100054A1 (fr) * 2011-12-27 2013-07-04 大正製薬株式会社 Dérivé de phényltriazole
EP3378477A1 (fr) * 2017-03-21 2018-09-26 BIOPROJET Pharma Nouvelles utilisations thérapeutiques de ligands h3
PT3598975T (pt) * 2018-07-27 2020-12-21 Bioprojet Soc Civ Novas combinações de um antagonista h3 e um inibidor da re-assimilação da noradrenalina, e suas utilizações terapêuticas

Also Published As

Publication number Publication date
KR102608265B1 (ko) 2023-11-30
PT3601252T (pt) 2021-03-31
SMT202100278T1 (it) 2021-07-12
HUE053710T2 (hu) 2021-07-28
EP3378858A1 (fr) 2018-09-26
LT3601252T (lt) 2021-04-26
RS61511B1 (sr) 2021-03-31
AU2018238260B2 (en) 2021-07-22
JP7235671B2 (ja) 2023-03-08
RU2019129432A3 (fr) 2021-07-01
DK3601252T3 (da) 2021-03-08
CA3056490A1 (fr) 2018-09-27
CN110891948A (zh) 2020-03-17
NZ757340A (en) 2026-03-27
IL269360B (en) 2022-10-01
IL269360A (en) 2019-11-28
PL3601252T3 (pl) 2021-08-02
AU2018238260A1 (en) 2019-10-10
MX389167B (es) 2025-03-20
WO2018172344A1 (fr) 2018-09-27
US11078183B2 (en) 2021-08-03
ZA201906202B (en) 2020-10-28
US20200024256A1 (en) 2020-01-23
EP3601252B1 (fr) 2021-02-17
KR20200008995A (ko) 2020-01-29
IL269360B2 (en) 2023-02-01
JP2020511507A (ja) 2020-04-16
EP3601252A1 (fr) 2020-02-05
MA48971B1 (fr) 2021-03-31
ES2868024T3 (es) 2021-10-21
BR112019019643A2 (pt) 2020-04-14
CN110891948B (zh) 2022-11-11
RU2019129432A (ru) 2021-03-18
CY1124114T1 (el) 2022-05-27
HRP20210312T1 (hr) 2021-04-02

Similar Documents

Publication Publication Date Title
PH12019550111A1 (en) Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors
MX2021013550A (es) Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas.
MX2019005569A (es) Nuevos derivados de quinolina.
UA103198C2 (en) Squaramide derivatives as cxcr2 antagonists
MX2018011419A (es) Moduladores de receptores estrogénicos.
NZ780787A (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
PH12016501962B1 (en) Macrocyclic pyridine derivatives
EA201492092A1 (ru) Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
MX2014003886A (es) Composiciones farmaceuticas de n-metil-2-[3-((e) 2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]benzamida.
PH12019500309A1 (en) Condensed bicyclic heterocycle derivatives as pest control agents
EA200970349A1 (ru) Ингибиторы металлопротеазы гетероциклического происхождения
EP3929198A4 (fr) Composé hétérocyclique, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
JOP20190262B1 (ar) مثبطات بيرازول magl
MX388589B (es) Nuevo uso terapeutico de h3-ligandos.
MA39983A (fr) Dérivés de carboxamide
EP3998270A4 (fr) Dérivé alcyne, son procédé de préparation et ses utilisations
EP4240330A4 (fr) Composition comprenant des composés hétérocycliques, son procédé de préparation et son application
PH12022552177A1 (en) Heteroaryl heterocyclic compounds and uses thereof
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX2018001979A (es) (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer.
MA48971B1 (fr) Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MY183769A (en) Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl-2-oxo-1,2-dihydropyridine-3-carboxamide